Home > Result Summaries: Compounds > ropinirole > Result Summary for 101468/125

Result Summary for 101468/125

Result Summary

Protocol ID:	101468/125
Clinical Study ID:	SKF-101468/125
Official Title:	A double-blind, multicentre, flexible dose, L-dopa controlled study of ropinirole to investigate A) neuroprotective effect as measured by 3D PET scanning, and B) ophthalmological safety, in patients with early Parkinson’s disease
Phase:	Phase 3
Study Indications or Diseases:	Parkinson Disease
Generic Name:	ropinirole
Trade/Product Name:	requip;requip
Approved Drug Label:	http://www.gsk.com/products.html
Results Summary:	Click here to download result summary.
Citations:	Whone, A, Watts, R, Stoessl, J, Davis, M, Reske, S, Nahmias, C, Lang, A, Rascol, O, Ribeiro, M, Remy, P, Poewe, W, Hauser, R, Brooks, D for the REAL-PET Study Group. Ann Neurol 2003;54:93-101. Brooks, D. J., 2212796 (Hammersmith Hospital, London, UK). Design and Demography of a Double-Blind Trial to Investigate Possible Neuroprotective Effects of Ropinirole vs L-Dopa with 3D18F-Dopa PET Scanning [P0675]. 6/17/2001: Hammersmith Hospital, London UK, 6/22/2001. 17th World Congress of Neurology; London; UK. London; UK; 2001 Jun 17; c2001. Slower Progression of Parkinson’s Disease with Ropinirole versus Levodopa: The REAL-PET Study